Mark Cuban has shifted his focus to the healthcare industry, driven by a desire to disrupt traditional practices. In 2022, he launched the Mark Cuban Cost Plus Drug Company, an online pharmacy that sells medications at cost plus a 15% markup. This approach aims to enhance transparency in a sector known for its complexity and high prices. Cuban's interest in healthcare began in 2017, particularly spurred by attempts to repeal Obamacare. He now oversees a company that offers over 6,000 generic and branded drugs, aiming to challenge the norms set by pharmacy benefit managers (PBMs) and insurance companies. Cuban has become an outspoken critic of PBMs, acknowledging that they often distract from the broader issues created by insurance companies. He argues that many CEOs, including himself in the past, lack the understanding to make informed choices about health plans, which leads to inflated costs. He highlighted a significant discrepancy in costs when he discovered his former basketball team, the Dallas Mavericks, paid $169,000 for generics that would have only cost $19,000 through Cost Plus. To tackle these inefficiencies, Cuban proposes state-controlled formularies to limit PBM influence and advocates for legislation that would allow cash payments for medications to count toward insurance deductibles. Cuban supports the Break Up Big Medicine Act, which aims to separate insurance companies from PBMs to create a more competitive market. He recently evaluated the TrumpRx initiative, a direct-to-consumer platform, giving it a rating of “A-” for its potential to reduce drug costs and increase access. Cuban is not overly concerned about potential pharmaceutical tariffs, believing that his company could adapt by producing generics domestically if FDA application costs can be reduced. He sees these regulatory hurdles as more significant obstacles than tariffs, indicating a practical approach to overcoming barriers in the pharmaceutical industry.